Sung Hwan Yoo

Prof. Sung Hwan Yoo

Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 December 2022 in Gut and Liver
Verified
Journal Article
Open access
PDF file
WSWolhwa Song
Wolhwa Song
Sung Hwan YooSung Hwan Yoo
Sung Hwan Yoo
JJJinsun Jang
Jinsun Jang
SBSu Jung Baik
Su Jung Baik
BLByoung Kwon Lee
Byoung Kwon Lee
JPJong Suk Park
Jong Suk Park
Wolhwa Song, Sung Hwan Yoo, Jinsun Jang, Su Jung Baik, Byoung Kwon Lee, Hyun Woong Lee, and Jong Suk Park. Gut and Liver 2023;17:130-8. https://doi.org/10.5009/gnl220041

1 January 2023 in Yonsei Medical Journal
Verified
Journal Article
Open access
PDF file
YKYuna Kim
Yuna Kim
Sung Hwan YooSung Hwan Yoo
Sung Hwan Yoo
JCJaeyoung Chun
Jaeyoung Chun
JKJie-Hyun Kim
Jie-Hyun Kim
YYYoung-Hoon Youn
Young-Hoon Youn
HPHyojin Park
Hyojin Park
Kim Y, et al. Yonsei Med J. 2023 Jan;64:e13. https://doi.org/10.3349/ymj.2022.0319


6 October 2023 in Asian Journal of Surgery
Verified
Journal Article
Open access
MJMan Ki Ju
Man Ki Ju
Sung Hwan YooSung Hwan Yoo
Sung Hwan Yoo
KCKi Hong Choi
Ki Hong Choi
Dong Sup YoonDong Sup Yoon
Dong Sup Yoon
JLjin hong lim
jin hong lim
Pure laparoscopic donor hepatectomy (PLDH) is an increasingly performed procedure despite its technical difficulties. This study introduced a selective liver parenchymal hanging maneuver and rubber band retraction technique for PLDH. We retrospectively reviewed perioperative data from 58 patients who underwent donor right hepatectomy (including right extended) between March 2009 and February 2021. Eighteen patients underwent open donor right hepatectomy (ODRH) and 38 patients underwent pure laparoscopic donor right hepatectomy (PLDRH). All PLDRH donors underwent the procedure without the need for open conversion. The median PLDRH operative time was 396.84 ± 72.459 min, the median PLDRH intraoperative bleeding amount was 496.05 ± 272.591 ml, and the warm ischemic time was 8.77 ± 3.062 min. Compared to ODRH, laparoscopic surgery showed further advantages in terms of postoperative hospital stay (10.94 ± 4.036 days vs. 8.03 ± 2.646 days, respectively, P = 0.01) and estimated blood loss (676.67 ± 321.046 ml vs. 496.05 ± 272.591 ml, respectively, P = 0.033). The selective liver parenchymal hanging maneuver and rubber band retraction technique is a simple and effective pure laparoscopic procedure for donor hepatectomy. Our results demonstrate the safety and feasibility of this technique.

8 January 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Sung Hwan YooSung Hwan Yoo
Sung Hwan Yoo
JNJi Hae Nahm
Ji Hae Nahm
HCHye Young Chang
Hye Young Chang
JLJungil Lee
Jungil Lee
JLjin hong lim
jin hong lim
HLHYUN WOONG LEE
HYUN WOONG LEE
Background: Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality worldwide, mainly due to its high recurrence rate after curative treatments. The macrotrabecular-massive (MTM) subtype has recently been recognized as an aggressive histologic variant associated with vascular invasion and poor differentiation. This study aimed to investigate the prognostic impact of the MTM subtype on recurrence after surgical resection of HCC. Methods: We retrospectively reviewed 171 patients who underwent curative hepatic resection for HCC between January 2007 and December 2017 at Gangnam Severance Hospital, Seoul, Korea. Clinicopathologic parameters, including immune-related features such as lymphoid infiltration and tertiary lymphoid structures (TLSs), were evaluated. Recurrence-free survival (RFS) and overall survival (OS) were analyzed using Kaplan–Meier and Cox regression analyses. Results: During a median follow-up of 4.4 ± 3.4 years, 74 patients (43.3%) experienced recurrence. The MTM subtype was significantly more frequent in the recurrence group than in the non-recurrence group (47.3% vs. 21.6%, p < 0.001). Multivariate analysis identified MTM subtype as an independent predictor of recurrence (hazard ratio, 1.88; 95% CI, 1.14–3.10; p = 0.013). Lymphoid infiltration and TLSs were not associated with prognosis. Kaplan–Meier analysis showed higher recurrence in MTM-positive cases (p = 0.001), whereas OS did not differ significantly (p = 0.094). Conclusions: The macrotrabecular-massive subtype is an independent histopathologic predictor of recurrence after curative resection in HCC. Incorporating MTM subtype recognition into postoperative risk assessment may enhance patient stratification and inform future adjuvant therapy strategies.

Verified
Journal Article
Open access
PDF file
IKIn Jung Kim
In Jung Kim
Sung Hwan YooSung Hwan Yoo
Sung Hwan Yoo
SKSora Kim
Sora Kim
YCYoung Youn Cho
Young Youn Cho
KYKi Young Yoo
Ki Young Yoo
HLHYUN WOONG LEE
HYUN WOONG LEE
Background: Hepatocellular carcinoma (HCC) rarely develops in patients with chronic hepatitis C (CHC) who achieve sustained virological response (SVR). We assessed the incidence of HCC in CHC patients with hemophilia after treatment with pegylated interferon plus ribavirin (PegIFN/RBV) and direct-acting antivirals (DAAs). Methods: Patients (n = 202) were enrolled between March 2007 and July 2019. A total of 139 patients were treated with PegIFN/RBV (genotype 1, n = 98; genotype 2, n = 41). Sixty-three patients were treated with DAAs (genotype 1, n = 44; genotype 2, n = 19). The cumulative incidence rates of HCC were estimated using the Kaplan–Meier method and compared using the log-rank test. Results: For genotype 1, SVR was achieved in 78.6% (77/98) and 90.9% (40/44) of patients in the PegIFN/RBV and DAAs groups, respectively. For genotype 2, SVR was achieved in 95.1% (39/41) and 94.7% (18/19) of patients in the PegIFN/RBV and DAAs groups, respectively. Six HCC cases were identified. The cumulative incidence of HCC was 4.1% at 14 years in PegIFN/RBV and 1.7% at 5 years in DAAs. The 14-year cumulative incidence of HCC was 1.9% in the SVR group and 21.7% in the no-SVR group in the PegIFN/RBV group (p < 0.001). Conclusions: Treatment with PegIFN/RBV led to stable SVR and a low incidence of HCC. Although the follow-up period was short, DAAs led to more stable SVR than PegIFN/RBV and a low incidence of HCC in CHC patients with hemophilia.